Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. The designation ...
Hosted on MSN1mon
Study: Merck and Daiichi's Lung Cancer Treatment Shows PromiseMerck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung ...
A mid-stage trial of Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan has hit the mark and will form the basis of regulatory filings for the drug later this year.
One such ADC is Patritumab Deruxtecan. Promising clinical activity is also seen when bispecific antibodies, like zenocutuzumab, target HER3 and HER2. Pharmaceutical companies actively pursue ...
GlobalData on MSN1mon
Daiichi Sankyo and MSD’s ADC improves progression-free survival in NSCLC trialDaiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback